IZIFUNDO ZAMACALA ANGAMANJE
I-CAR-T ye-Glioblastoma
I-Glioblastoma ingenye yezimila zobuchopho ezivame kakhulu neziyinselele kubantu abadala. Ivela kumaseli e-glial ebuchosheni futhi yaziwa ngokukhula kwayo okusheshayo kanye nokuthambekela kokungena ezicutshini ezizungezile, okwenza ukususwa ngokuphelele kube nzima. Izimpawu zingafaka phakathi ikhanda, ukuquleka, izinguquko zokuqonda, kanye nokuntuleka kwezinzwa, kuye ngokuthi isimila sikuphi. Nakuba ukwelashwa okujwayelekile kungasiza ekuphatheni lesi sifo, iziguli eziningi zifuna ukwelashwa okuqondiwe ukuze zithuthukise imiphumela kanye nekhwalithi yokuphila.
Ukwelashwa kwe-CAR-T komdlavuza wesisu
Ukwelashwa ngamaseli e-CAR-T kuyindlela yokwelapha nge-immunotherapy eyenzelwe wena uqobo esetshenziswa kakhulu ekwelapheni umdlavuza wesisu. I-BIOOCUS isungule imikhiqizo ye-CAR-T ehlose ama-antigen athile omdlavuza wesisu njenge-Claudin18.2 kanye ne-HER2, okubonisa ukusebenza kahle okukhulu ezigulini ezihlulekile ukwelashwa okuningi kwangaphambilini—isibonelo, i-CT041 ithole i-ORR engu-57.1%, i-DCR engu-75%, kanye nesilinganiso sokusinda sezinyanga eziyi-6 esingu-81.2%. Isebenzisa ipulatifomu yamazwe ngamazwe yezinga le-GMP, ithimba lochwepheshe elihlanganisa imikhakha eminingi, kanye nokuhlangenwe nakho okubanzi kwezokwelapha emhlabeni jikelele, i-BIOOCUS inikeza ikhambi lokwelapha le-CAR-T eliphephile, elisebenzayo, neliphelele leziguli ezinomdlavuza wesisu.
I-CAR-T ye-Systemic Lupus Erythematosus (SLE)
Ukwelashwa ngamaseli e-CAR-T (Chimeric Antigen Receptor T) kuyindlela entsha yokwelapha ngezifo ezithathelwanayo eye yabonisa amandla ekwelapheni i-SLE ngokubhekisisa amaseli e-B, adlala indima ebalulekile ekuqaliseni kwalesi sifo. Ku-SLE, amaseli e-B akhiqiza ama-autoantibodies ahlasela izicubu zomzimba, okuholela ekuvuvukeni okungapheli kanye nomonakalo wezitho zomzimba. Ukwelashwa kwe-CAR-T kusebenza ngobunjiniyela bamaseli e-T ukuveza i-receptor (CAR) ebhekisisa ngqo i-CD19, uphawu kumaseli e-B, okuholela ekubhujisweni kwala maseli e-B ayingozi.
Amaseli e-CAR-T ahlasela amaseli e-CD19+ B ahlinzeka ngokuncipha okusebenzayo nokuqhubekayo kwamaseli e-B uma kuqhathaniswa nezinye izindlela zokwelapha, ezihlasela i-CD20 kodwa zehluleka ukuqeda amaseli e-plasma ahlala isikhathi eside. Lokhu kuncipha okukhulu kwamaseli e-B kungaholela ekukhululweni kwezimpawu ze-SLE ngokuqeda amaseli abangela ukukhiqizwa kwama-autoantibodies. Izifundo ziphinde zihlole i-CAR-Treg (amaseli e-CAR-T aklanyelwe ukulawula izimpendulo zomzimba) ukuze kubuyiselwe ukubekezelelana komzimba nokunciphisa umsebenzi wokuzivikela komzimba.
I-FUCASO: Ukwelashwa kwe-BCMA CAR-T okuGuquliwe okuSebenza kahle kanye nokuphepha okungenakuqhathaniswa
I-FUCASO iyindlela yokwelapha i-CAR-T egxile ku-BCMA eyenziwe yi-IASO BIO, enikeza ukusebenza kahle nokuphepha okungenakuqhathaniswa kwe-multiple myeloma ephinde yabuya noma engaphili kahle. Njengoba inezinga eliphezulu lokusabela, ukuphulukiswa okuhlala isikhathi eside, kanye nephrofayili yokuphepha eqinile, i-FUCASO inikeza ithemba elisha ezigulini futhi ibeka indinganiso entsha ekwelashweni kwe-CAR-T.
Ukubuka Konke Okuphelele Kokwelashwa Okubangela Umdlavuza Wegazi
I-CAR-T Therapy, efushanisiwe nelithi Chimeric Antigen Receptor T-Cell Immunotherapy, iyindlela yokwelapha izakhi zofuzo ethuthukisiwe ehilela ukuguqula izakhi zofuzo zamaseli e-T esiguli ukuze ihlose futhi ibhubhise amaseli omdlavuza. Ngokungafani nemithi yendabuko, ukwelashwa kwe-CAR-T kwenzelwe isiguli ngasinye futhi kudinga ukuqoqa amaseli e-T egazini lesiguli ngaphambi kokuwabuyisela emzimbeni ngemva kobunjiniyela bezakhi zofuzo.